Biotech Values

[mcbio]

For those with nuc: GILD is the biggest winner! IDIX nuc doesn't look that bad now, just a little bit slow acting, better than serious safety issue. VRTX is in much better position with two different nuc candidates.

I think it's certainly good news for GILD. IDIX presumably gets a lift by default with one less nuke competitor, though I still don't care for them at this valuation. I still say VRTX will eventually need a 2nd gen PI or NS5A. As a Medivir long, I'm a bit bummed that the BMY nuke failed as it's one less option for TMC435 to be paired with. But, TMC435 still has other options to be paired with and Medivir still has their own nukes, albeit at an earlier stage (Phase 1 to start for one of them in 4Q12).